Compare OMH & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMH | MRKR |
|---|---|---|
| Founded | 2015 | N/A |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7M | 23.0M |
| IPO Year | 2022 | 2010 |
| Metric | OMH | MRKR |
|---|---|---|
| Price | $1.37 | $1.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $11.25 |
| AVG Volume (30 Days) | 25.5K | ★ 116.7K |
| Earning Date | 11-28-2025 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.40 | N/A |
| Revenue Next Year | $23.07 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.59 | $0.81 |
| 52 Week High | $4.33 | $4.07 |
| Indicator | OMH | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 52.67 | 40.49 |
| Support Level | $1.03 | $0.83 |
| Resistance Level | $1.35 | $1.44 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 75.61 | 18.33 |
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.